share_log

Smith & Nephew's Implant Shows 86% Reduction In Re-Tear Rates After Shoulder Surgery

Benzinga Real-time News ·  Sep 14, 2022 12:26
  • Smith & Nephew plc (NYSE:SNN) announced new data furthering several published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair.
  • The REGENETEN Bioinductive Implant is part of Smith & Nephew's Advanced Healing Solutions portfolio.
  • The goal of rotator cuff repair surgery is to help restore the shoulder's function and flexibility and relieve the pain that other treatments can't control.
  • Also Read: Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit.
  • Interim analysis from a randomized controlled trial shows a significant reduction in the re-tear rate of full-thickness rotator cuff repairs when using the REGENETEN Bioinductive Implant.
  • At 12 months follow-up, repairs with the added REGENETEN Bioinductive Implant resulted in significantly lower re-tear rates than those with a TOE repair alone.
  • Specifically, patients who received a REGENETEN Bioinductive Implant presented a re-tear rate of 3.5%. (n=29).
  • Patients who received a transosseous equivalent repair alone presented a re-tear rate of 25%, which is in line with published re-tear rates on similar tear types.
  • There were no differences in postoperative complications between groups.
  • Price Action: SNN shares are trading lower by 1.85% at $24.93 on the last check Wednesday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment